Corcept Therapeutics Forecasts 2026 Revenue of $1.1 Billion-$1.2 Billion

PUBT · 4d ago
Corcept Therapeutics Forecasts 2026 Revenue of $1.1 Billion-$1.2 Billion
  • Corcept Therapeutics forecasts 2026 revenue of $1.1 billion to $1.2 billion.
  • Third-quarter revenue totaled $341 million, up from $256 million in the second quarter.
  • Korlym generated third-quarter revenue of $249 million; Lifyorli contributed $91 million.
  • Cash stood at $662 million at the end of the third quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.